Biotech Values

[DewDiligence]

EXAS—Trials are ongoing to answer this question.

Please be more specific. Exactly how will cumulative sensitivity be quantified by the trials in question?

Until the final results are in, should the world not use a test that improves screening relative to the FIT and has the potential to reduce the rate of CRC?

That’s a separate issue entirely. I’m addressing whether the comments made by Kevin Conroy about cumulative sensitivity, which I excerpted from the CC transcript in #msg-87173585, should be taken seriously by investors.

p.s. As the share price continues to fall, EXAS is becoming more attractive as a buyout candidate for a firm who has the desire and the resources to improve the Cologuard test. At the right valuation, I might yet take a position in the stock.